David J. Newman retired from the position of chief of the Natural Products Branch (NPB) in the Developmental Therapeutics Program at the National Cancer Institute (NCI) in Frederick, Maryland, in early January 2015.
He is the author or coauthor of over 180 papers, reviews, and book chapters (and an editor, with Gordon M. Cragg and David Kingston, of Anticancer Agents from Natural Products), and holds 18 patents, mainly on microbial products. He is still associated with the NPB/NCI as a special volunteer and also has a small consulting business.

Gordon M. Cragg obtained his undergraduate training in chemistry at Rhodes University, South Africa, and his DPhil (organic chemistry) from Oxford University.
He has established collaborations between the NCI and organizations in many countries, promoting drug discovery from their natural resources. He has authored or coauthored over 180 papers, reviews, and book chapters.

Paul G. Grothaus earned a BSChem from Creighton University in 1977 and his PhD from Purdue University in 1983, where he completed the first enantiospecific total synthesis of a trichothecene mycotoxin, anguidine.
In 2007, he joined the Natural Products Branch of the National Cancer Institute in Frederick, Maryland, where he coordinates biomass collections, biological screening of extracts, and collaborations with external natural product researchers. Dr. Grothaus is the author or coauthor of 24 papers, reviews, and book chapters and holds 5 patents.